## Daniela Scattolin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10196713/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	First-Line Osimertinib in Patients with <i>EGFR</i> -Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study. Oncologist, 2022, 27, 87-e115.	3.7	25
2	Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines. Future Oncology, 2021, 17, 2513-2527.	2.4	7
3	Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. Clinical Lung Cancer, 2020, 21, 1-14.e3.	2.6	19
4	1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2) Tj ETQq0	0 0 <b>10</b> 2rgBT	/Oøerlock 10